Revitope Oncology Signs License Agreement Providing Genmab A/S Access To Revitope's Conditional TCE Technology, TwoGATE; Revitope Oncology To Receive Upfront Payment Of $9M With Milestone And Fee Payments Up To $600M Plus Tiered Single-Digit Royalties On Sales Of Successfully Commercialized Therapies
- Genmab secures rights to Revitope's proprietary, conditional T Cell Engagement (TCE) TwoGATE technology for conducting research against multiple drug target pairs with options for exclusive worldwide development and commercialization for up to three resulting products
- Revitope to receive an upfront payment of USD $9 million with milestone and fee payments up to USD $600 million plus tiered single-digit royalties on sales of successfully commercialized therapies
BOSTON, Oct. 29, 2024 /PRNewswire/ -- Revitope Oncology Inc. (Revitope), a biotechnology company advancing a new class of precision cancer immunotherapies, announced today that it has signed a license agreement providing Genmab A/S (Genmab) access to Revitope's conditional TCE technology, TwoGATE. Genmab is granted exclusive rights to utilize TwoGate for multiple drug target pairs during a multi-year research period, including the option to take up to three exclusive licenses for worldwide development and commercialization of the resulting products.
TwoGATE leverages the dual antigen binding requirement of a unique split paratope that assembles on the tumor cell surface to potently engage T cells with high precision, potentially addressing key areas of unmet need in the treatment of solid tumors.
